Aaron Seth Rosenberg, MD, MS, associate professor, Department of Internal Medicine, Division of Hematology and Oncology, UC Davis Health, discusses the emerging role of minimal residual disease (MRD) to guide treatment decisions in multiple myeloma.

The findings from currently enrolling clinical trials could provide insight into how to better adapt treatments to patient responses, Rosenberg says. Ongoing trials are evaluating how patients who don’t achieve MRD negativity after transplant fare with escalated treatment approaches, Rosenberg continues. Additional studies are testing whether it is feasible to stop maintenance therapy in patients who are MRD negative 2 years post-transplant, Rosenberg adds.

Sustained MRD negativity could offer an end point to guide therapy escalation in multiple myeloma, Rosenberg says. Patients who achieve MRD negativity could potentially deescalate therapy rather than receive continuous maintenance therapy, Rosenberg concludes.

Videos

Aaron Seth Rosenberg, MD, MS, discusses the emerging role of minimal residual disease to guide treatment decisions in multiple myeloma. 


Dr. Rosenberg on Adapting Treatment Decisions Based on MRD in Multiple Myeloma 

Aaron Seth Rosenberg, MD, MS, associate professor, Department of Internal Medicine, Division of Hematology and Oncology, UC Davis Health, discusses the potential clinical implications of the phase 2 GRIFFIN trial (NCT02874742) in multiple myeloma.

Initial findings from the GRIFFIN trial demonstrated improved efficacy with the combination of daratumumab (Darzalex), lenalidomide (Revlimid), bortezomib (Velcade), and dexamethasone (D-RVd) followed by daratumumab maintenance vs RVd alone in patients with newly diagnosed, transplant-eligible multiple myeloma.

Although the data remain immature, the findings from the GRIFFIN trial have changed frontline treatment for some patients with transplant-eligible multiple myeloma, Rosenberg says. Providers interested in the early adoption of a quadruplet-based regimen may be comfortable this approach given the available data from the study, Rosenberg adds.

Aaron Seth Rosenberg, MD, MS, discusses the potential clinical implications of the phase 2 GRIFFIN trial in multiple myeloma.  



Aaron Seth Rosenberg, MD, MS

Articles

Dr. Rosenberg on Adapting Treatment Decisions Based on MRD in Multiple Myeloma

Dr. Rosenberg on the Potential Clinical Implications of the GRIFFIN Trial in Multiple Myeloma